(MDT) Medtronic - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 100.336m USD | Total Return: 0.2% in 12m
Avg Turnover: 781M
EPS Trend: -1.9%
Qual. Beats: -1
Rev. Trend: 98.2%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Medtronic PLC is a global leader in medical technology, specializing in device-based therapies across four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company manufactures a diverse range of critical hardware, including pacemakers, spinal implants, surgical robotics, and continuous glucose monitoring systems. Headquartered in Ireland, Medtronic serves a broad spectrum of medical specialists and healthcare systems worldwide.
The medical device industry operates within a high-barrier-to-entry environment due to intensive R&D requirements and stringent regulatory approval processes from bodies like the FDA. Medtronic utilizes a diversified business model that balances mature, high-volume products like surgical staples with high-growth innovation areas such as AI-powered surgical analytics and remote patient monitoring software.
To deepen your understanding of these business segments, consider reviewing the detailed financial breakdowns available on ValueRay.
- Regulatory approval and adoption of Hugo robotic-assisted surgery system drive long-term growth
- Continuous glucose monitoring innovation and insulin pump integration determine diabetes segment market share
- Cardiovascular portfolio revenue depends on procedure volumes and transcatheter aortic valve replacement demand
- Global supply chain stability and healthcare labor shortages impact manufacturing costs and margins
| Net Income: 4.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.16 > 1.0 |
| NWC/Revenue: 41.08% < 20% (prev 32.15%; Δ 8.93% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.29b > Net Income 4.61b |
| Net Debt (27.0b) to EBITDA (9.36b): 2.88 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2% |
| Gross Margin: 61.95% > 18% (prev 0.65%; Δ 6.13k% > 0.5%) |
| Asset Turnover: 39.11% > 50% (prev 36.90%; Δ 2.21% > 0%) |
| Interest Coverage Ratio: 8.81 > 6 (EBITDA TTM 9.36b / Interest Expense TTM 712.0m) |
| A: 0.16 (Total Current Assets 24.1b - Total Current Liabilities 9.49b) / Total Assets 91.5b |
| B: 0.35 (Retained Earnings 32.3b / Total Assets 91.5b) |
| C: 0.07 (EBIT TTM 6.27b / Avg Total Assets 90.7b) |
| D: 0.66 (Book Value of Equity 27.8b / Total Liabilities 42.3b) |
| Altman-Z'' = 3.35 = A |
| DSRI: 0.01 (Receivables 87.0m/6.12b, Revenue 35.5b/33.2b) |
| GMI: 1.05 (GM 61.95% / 65.27%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 35.5b / 33.2b) |
| TATA: -0.03 (NI 4.61b - CFO 7.29b) / TA 91.5b) |
| Beneish M = -3.78 (Cap -4..+1) = AAA |
As of May 23, 2026, the stock is trading at USD 78.15 with a total of 7,593,369 shares traded.
Over the past week, the price has changed by +3.22%,
over one month by -5.55%,
over three months by -19.64% and
over the past year by +0.23%.
Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 108 | 38.2% |
P/E Forward = 12.8041
P/S = 2.8276
P/B = 2.0483
P/EG = 1.3629
Revenue TTM = 35.5b USD
EBIT TTM = 6.27b USD
EBITDA TTM = 9.36b USD
Long Term Debt = 27.8b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 58.0m
Net Debt = 27.0b USD (calculated: Debt 28.1b - CCE 1.15b)
Enterprise Value = 127b USD (100b + Debt 28.1b - CCE 1.15b)
Interest Coverage Ratio = 8.81 (Ebit TTM 6.27b / Interest Expense TTM 712.0m)
EV/FCF = 23.53x (Enterprise Value 127b / FCF TTM 5.41b)
FCF Yield = 4.25% (FCF TTM 5.41b / Enterprise Value 127b)
FCF Margin = 15.25% (FCF TTM 5.41b / Revenue TTM 35.5b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.5b)
Gross Margin = 61.95% ((Revenue TTM 35.5b - Cost of Revenue TTM 13.5b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 1.39 (Enterprise Value 127b / Total Assets 91.5b)
Interest Expense / Debt = 2.53% (Interest Expense 712.0m / Debt 28.1b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.14b (EBIT 6.27b * (1 - 18.09%))
Current Ratio = 2.54 (Total Current Assets 24.1b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.1b / totalStockholderEquity, last quarter 49.0b)
Debt / EBITDA = 2.88 (Net Debt 27.0b / EBITDA 9.36b)
Debt / FCF = 4.99 (Net Debt 27.0b / FCF TTM 5.41b)
Total Stockholder Equity = 48.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.09% (Net Income 4.61b / Total Assets 91.5b)
RoE = 9.54% (Net Income TTM 4.61b / Total Stockholder Equity 48.4b)
RoCE = 8.23% (EBIT 6.27b / Capital Employed (Equity 48.4b + L.T.Debt 27.8b))
RoIC = 6.34% (NOPAT 5.14b / Invested Capital 81.0b)
WACC = 5.78% (E(100b)/V(128b) * Re(6.82%) + D(28.1b)/V(128b) * Rd(2.53%) * (1-Tc(0.18)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.67 | Cagr: -1.47%
[DCF] Terminal Value 75.30% ; FCFF base≈5.43b ; Y1≈5.41b ; Y5≈5.63b
[DCF] Fair Price = 47.31 (EV 87.7b - Net Debt 27.0b = Equity 60.7b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow -1.04% → 2.50% )
EPS Correlation: -1.95 | EPS CAGR: -0.11% | SUE: -4.0 | # QB: -1
Revenue Correlation: 98.17 | Revenue CAGR: 4.32% | SUE: 1.63 | # QB: 3
EPS current Quarter (2026-07-31): EPS=1.38 | Chg30d=+0.35% | Revisions=+0% | Analysts=20
[Analyst] Revisions Ratio: +0%